Should retest the highs of early March with clinical trials in US announced with China and South Korea to follow. Expect negative stories of lawsuits and historical track record to persist otherwise I agree with many that INO with VGX-3100 could have a market cap similar in range to Moderna MRNA 11B+. That would make INO share price 9x in the 72-80 range.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款阅读更多信息。